INAB

In8bio, Inc. is a New York-based clinical-stage biotechnology firm pioneering the development of innovative cancer therapies through genetically modified gamma-delta T cells. Focused on both autologous and allogeneic cell therapies, the company is strategically targeting solid tumors, thereby establishing itself as a key player in the immuno-oncology space. With a robust pipeline of proprietary treatments, In8bio is committed to meeting critical unmet needs in cancer care, aiming to deliver transformative solutions that could significantly alter the future of oncology therapeutics.